Treatment of hepatitis C in 2011: What can we expect?

Current Gastroenterology Reports

Volumn 12, Issue 1, 2010, Pages 70-75

  Shiffman, Mitchell L ^a  

^a Mary Immaculate Hospital   (United States)

Author keywords

HCV; Peginterferon; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; INTERLEUKIN 28; INTERLEUKIN 28B; PEGINTERFERON; PLACEBO; PROTEINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ANEMIA; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSGEUSIA; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERBILIRUBINEMIA; LIVER FIBROSIS; LIVER TOXICITY; LYMPHOCYTOPENIA; NAUSEA; NEUTROPENIA; NONHUMAN; QT PROLONGATION; RELAPSE; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIROLOGY; VOMITING;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FORECASTING; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERLEUKINS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RIBAVIRIN;

EID: 77950864210     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0085-4     Document Type: Review

References (27)

1. MW Fried ML Shiffman KR Reddy, et al. 2002 Combination of peginterferon alfa-2a (40 kd) plus ribavirin in patients with chronic hepatitis C virus infection N Engl J Med 347 975 982 10.1056/NEJMoa020047 1:CAS:528: DC%2BD38Xnt12rtb0%3D 12324553
2. MP Manns JG McHutchinson SC Gordon, et al. 2001 Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 958 965 10.1016/S0140-6736(01)06102-5 1:CAS:528:DC%2BD3MXntF2qtb8%3D 11583749 (Pubitemid 32913521)
3. JG McHutchison EJ Lawitz ML Shiffman, et al. 2009 for the IDEAL study team: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 580 593 10.1056/NEJMoa0808010 1:CAS:528: DC%2BD1MXps1Kjuro%3D 19625712
4. H El Makhzangy G Esmat M Said, et al. 2009 Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4 J Med Virol 81 1576 1583 10.1002/jmv.21570 19626613
5. ML Yu WL Chuang 2009 Treatment of chronic hepatitis C in Asia: when East meets West J Gastroenterol Hepatol 24 336 345 10.1111/j.1440-1746.2009.05789.x 1:CAS:528:DC%2BD1MXltFCgtL8%3D 19335784
6. A Wasley MJ Alter 2000 Epidemiology of hepatitis C: geographic differences and temporal trends Semin Liver Dis 20 1 16 10.1055/s-2000-9506 1:STN:280:DC%2BD3M%2Fit12ltg%3D%3D 10895428
7. V Fensterl GC Sen 2009 Interferons and viral infections Biofactors 35 14 20 10.1002/biof.6 1:CAS:528:DC%2BD1MXnsVSmtb8%3D 19319841
8. P Martin DM Jensen 2008 Ribavirin in the treatment of chronic hepatitis C J Gastroenterol Hepatol 23 844 855 10.1111/j.1440-1746.2008.05398.x 1:CAS:528:DC%2BD1cXptFyls7o%3D 18565019 (Pubitemid 351806583)
9. JG McHutchison GT Everson SC Gordon, et al. 2009 Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 1827 1838 10.1056/NEJMoa0806104 1:CAS:528:DC%2BD1MXlsVGmtrc%3D 19403902 The combination of telaprevir, peginterferon, and ribavirin yields high rates of RVR and SVR with just 24 weeks' total duration of therapy
10. C Hézode N Forestier G Dusheiko, et al. 2009 Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 1839 1850 10.1056/NEJMoa0807650 19403903
11. P Kwo EJ Lawitz J McCone, et al. 2008 HCV sprint-1: boceprevir plus peginterferon alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients Hepatology 48 Suppl 4 1027A
12. ML Shiffman 2008 Optimizing the current therapy for chronic hepatitis C virus. Peginterferon and ribavirin dosing and the utility of growth factors Clin Liver Dis 12 487 505 10.1016/j.cld.2008.03.004 18625425 (Pubitemid 351952474)
13. P Ferenci MW Fried ML Shiffman, et al. 2005 Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin J Hepatol 43 453 471 10.1016/j.jhep.2005.04.009 (Pubitemid 41111423)
14. ML Shiffman F Suter BR Bacon, et al. 2007 Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 N Engl J Med 357 124 134 10.1056/NEJMoa066403 1:CAS:528:DC%2BD2sXns12qurw%3D 17625124 (Pubitemid 47057730)
15. P Ferenci H Laferl TM Scherzer, et al. 2008 Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response Gastroenterology 135 451 458 10.1053/j.gastro.2008.04.015 1:CAS:528:DC%2BD1cXhtVCqsL%2FJ 18503773
16. DM Jensen TR Morgan P Marcellin, et al. 2006 Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy Hepatology 43 954 960 10.1002/hep.21159 1:CAS:528:DC%2BD28XkvFGmt7o%3D 16628671 (Pubitemid 43724620)
17. ML Shiffman FM Hamzeh RT Chung 2008 Effect of time to response on viral breakthrough and relapse rates in patients infected with HCV genotype 1 and treated with peginterferon alfa-2a plus ribavirin Hepatology 48 Suppl 862A
18. SJ Hadziyannis H Sette Jr TR Morgan, et al. 2004 Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346 355 1:CAS:528:DC%2BD2cXitlOktrg%3D 14996676
19. B Willems SJ Hadziyannis TR Morgan, et al. 2007 Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virological response? J Hepatol 46 S6 10.1016/S0168-8278(07) 61606-7
20. T Berg M von Wagner S Nasser, et al. 2006 Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin Gastroenterology 130 1086 1097 10.1053/j.gastro.2006.02.015 1:CAS:528:DC%2BD28XksFWmuro%3D 16618403
21. JM Sánchez-Tapias M Diago P Escartín, et al. 2006 Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment Gastroenterology 131 451 460 10.1053/j.gastro.2006.05.016 16890599 (Pubitemid 44142452)
22. BL Pearlman C Ehleben S Saifee 2007 Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders Hepatology 46 1688 1694 10.1002/hep.21919 1:CAS:528:DC%2BD2sXhsVGiur7O 18046717
23. T Asselah Y Benhamou P Marcellin 2009 Protease and polymerase inhibitors for the treatment of hepatitis C Liver Int 29 Suppl 1 57 67 10.1111/j.1478-3231. 2008.01928.x 19207967
24. McHutchison JG, Manns MP, Muir A, et al.: Prove 3 final results and 1-year durability of SVR with telaprevir-based regimen in hepatitis C genotype 1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy. Hepatology 2009, in press.
25. F Poordad ML Shiffman K Sherman, et al. 2008 A study of telaprevir with peginterferon alfa-2a and ribavirin in subjects with well-documented prior peginterferon/ribavirin null response, non-response or relapse: preliminary results J Hepatology 48 Suppl 2 S374 S375 10.1016/S0168-8278(08)61002-8
26. Kwo PY, Lawitz E, McCone J, et al.: High sustained virologic response in genotype 1 null responders to peg-interferon alfa-2b plus ribavirin when treated with boceprevir combination therapy. Hepatology 2009, in press.
27. D Ge J Fellay AJ Thompson, et al. 2009 Genetic variation in IL-28B predicts hepatitis C treatment-induced viral clearance Nature 461 399 401 10.1038/nature08309 1:CAS:528:DC%2BD1MXpvFCrtbw%3D 19684573 The identification of the IL-28B polymorphism, which predicts SVR, will significantly enhance the selection of patients who will receive peginterferon and ribavirin treatment before the introduction of DAA in late 2011